Vertex Pharmaceuticals Announces FDA Approval for ALYFTREK to Treat Cystic Fibrosis

Details

Food and Drug Administration (FDA) approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in individuals aged 6 and older with specific mutations. The drug's wholesale acquisition cost in the U.S. is set at $370,269 annually. This marks a significant milestone for Vertex Pharmaceuticals in addressing cystic fibrosis, offering a new therapeutic option for patients.

Items reported

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.